Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension

Journal of Human Hypertension volume 15, pages 135–141 (2001)Cite this article

Abstract

Background: The effect of controlled-onset, extended-release (COER) verapamil on haemodynamic parameters in obese and non-obese patients is evaluated in this analysis.

Methods: Data were pooled from three clinical trials evaluating efficacy and tolerability of COER-verapamil. Hypertensive men and women (stage I to III) were randomised to COER-verapamil (180–540 mg at bedtime) or placebo for 4–8 weeks and stratified according to body mass index (BMI-obese >28 kg/m2). Efficacy was assessed as change from baseline in blood pressure (BP), heart rate, and rate-pressure product during four time periods throughout the dosing interval. Safety and tolerability were assessed by monitoring all adverse events and changes in metabolic laboratory parameters.

Results: Reductions in all haemodynamic parameters were significantly greater following COER-verapamil compared with placebo for all time periods. The haemodynamic effects of COER-verapamil in obese (n= 166, BMI = 32.8 kg/m2) and non-obese patients (n = 115, BMI = 25.0 kg/m2) were similar. COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0.001).

Conclusions: COER-verapamil is effective in reducing BP, heart rate, and rate-pressure product independently of BMI.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, CT, USA

    WB White

  2. Department of Preventive Medicine, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA

    WJ Elliott & HR Black

  3. Biostatistics Department, Pharmanet, Princeton, NJ, USA

    MF Johnson

Authors
  1. WB White
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. WJ Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MF Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. HR Black
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was presented, in part, at the 100th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, March 18, 1999, in San Antonio, Texas, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

White, W., Elliott, W., Johnson, M. et al. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 15, 135–141 (2001). https://doi.org/10.1038/sj.jhh.1001137

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001137

Keywords

This article is cited by

Search

Advanced search

Quick links